PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours ; volume:12 ; number:1 ; day:25 ; month:10 ; year:2012 ; pages:1-10 ; date:12.2012
BMC cancer ; 12, Heft 1 (25.10.2012), 1-10, 12.2012
- Urheber
-
McKeage, Mark J.
- Beteiligte Personen und Organisationen
-
Jameson, Michael B.
Ramanathan, Ramesh K.
Rajendran, Joseph
Gu, Yongchuan
Wilson, William R.
Melink, Teresa J.
Tchekmedyian, N Simon
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-496
- URN
-
urn:nbn:de:1111-201603041960
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- McKeage, Mark J.
- Jameson, Michael B.
- Ramanathan, Ramesh K.
- Rajendran, Joseph
- Gu, Yongchuan
- Wilson, William R.
- Melink, Teresa J.
- Tchekmedyian, N Simon
- SpringerLink (Online service)
Ähnliche Objekte (12)
A Novel Fluorescent Gemcitabine Prodrug That Follows a Nucleoside Transporter‐Independent Internalization and Bears Enhanced Therapeutic Efficacy With Respect to Gemcitabine
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Gemcitabine and Docetaxel for Epithelioid Sarcoma : Results from a Retrospective, Multi-Institutional Analysis
Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
A Novel Fluorescent Gemcitabine Prodrug That Follows a Nucleoside Transporter‐Independent Internalization and Bears Enhanced Therapeutic Efficacy With Respect to Gemcitabine
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Gemcitabine and Docetaxel for Epithelioid Sarcoma : Results from a Retrospective, Multi-Institutional Analysis
Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
A Novel Fluorescent Gemcitabine Prodrug That Follows a Nucleoside Transporter‐Independent Internalization and Bears Enhanced Therapeutic Efficacy With Respect to Gemcitabine
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Gemcitabine and Docetaxel for Epithelioid Sarcoma : Results from a Retrospective, Multi-Institutional Analysis
Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy